Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast CancerJessica J. Tao, Maurizio Scaltriti, Pau Castel et al.|Science Signaling|2014Cited by 166
Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor of PKCsDivya Ram Jayaram, Etta Livneh, Sigal A. Frost et al.|Proceedings of the National Academy of Sciences|2021Cited by 55
Activation of the <scp>EGFR</scp> / <scp>PI3K</scp> / <scp>AKT</scp> pathway limits the efficacy of trametinib treatment in head and neck cancerOfra Novoplansky, Moshe Elkabets|Molecular Oncology|2023Cited by 33
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancerOfra Novoplansky, Moshe Elkabets|International Journal of Cancer|2019Cited by 31
Enhanced ZnR/GPR39 Activity in Breast Cancer, an Alternative Trigger of Signaling Leading to Cell GrowthHila Ventura-Bixenshpaner, Michal Hershfinkel, Hila Asraf et al.|Scientific Reports|2018Cited by 20